Treating dyslipidemia
|
|
- Asher Weaver
- 5 years ago
- Views:
Transcription
1 Treating dyslipidemia in patients with type 2 diabetes mellitus 18 The Nurse Practitioner Vol. 40, No. 18
2 2.0 CONTACT HOURS 1.0 CONTACT HOURS Abstract: Type 2 diabetes mellitus is associated with significant cardiovascular morbidity and mortality. Diabetic dyslipidemia is a major cause of cardiovascular complications and a key area for intervention. The blood cholesterol treatment guideline released in 2013 and strategies to reduce cardiovascular risk are outlined and addressed in this article. By Michelle L. Frank, MSN, APRN, FNP-C and Annie M. Gerhardt, DNP, APRN, FNP-C A therogenic dyslipidemia is a key modifiable risk factor for macrovascular events and continues to be problematic. Prevention and treatment of dyslipidemia, as well as tight control of BP and glycemia, are part of the optimal approach to reducing residual vascular risk in patients with type 2 diabetes mellitus (T2DM). The American College of Cardiology/American Heart Association (ACC/AHA) released the new guideline for the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. 1 Lifestyle therapy and treatment with HMG-CoA reductase inhibitors (statins) (according to the four major statin groups and a new global risk assessment tool) provide early interruption to the natural progression of atherosclerosis D4Medical/Phototake Significance of the problem Cardiovascular disease (CVD) is the largest contributor to the direct and indirect costs of diabetes. 6 Common conditions coexisting with T2DM, such as hypertension and dyslipidemia, are clear risk factors for CVD. Epidemiologic studies and clinical trials have demonstrated that patients with diabetes are at increased risk for CVD and that T2DM itself confers independent risk. Numerous studies have Keywords: cholesterol reduction, diabetes, dyslipidemia, endocrine, hyperlipidemia, macrovascular risk reduction, primary care, statin therapy, type 2 diabetes mellitus The Nurse Practitioner January August
3 demonstrated the importance of controlling individual cardiovascular risk factors and the positive impact of preventing or slowing CVD in patients with T2DM. Dyslipidemia is an important, modifiable risk factor in patients at risk for coronary events and represents a key area for intervention in patients with T2DM. 1-3,6,7 Pathophysiology Typical diabetic dyslipidemia includes hypertriglyceridemia, low high-density lipoprotein cholesterol (HDL-C), and mildly elevated low-density lipoprotein cholesterol (LDL-C) with a predominance of small, dense LDL particles. 2,3,6,8 The smaller LDL particles can infiltrate the arterial wall more readily, are more easily oxidized, and do not bind as efficiently to the LDL receptor. This ultimately results in impaired hepatic clearance of cholesterol. The mechanisms leading to hypertriglyceridemia directly relate to insulin resistance and hyperglycemia. The end result is overproduction of triglyceride-rich lipoproteins from the liver, decreased clearance of triglyceriderich lipoproteins, and, in some cases, an altered postprandial lipoprotein metabolism. This complex dyslipidemia (termed atherogenic dyslipidemia, diabetic dyslipidemia, or dyslipidemia of insulin resistance) is indicative of underlying insulin resistance and plays a key role in the increased cardiovascular risk in patients with T2DM. 6,9 Current practice guidelines The updated American College of Cardiology (ACC) and American Heart Association (AHA) guideline for the treatment of blood cholesterol was published in Recommendations include lowering LDL-C as the primary target followed by increasing HDL-C and lowering triglycerides (TG). The new guideline differs significantly from the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults in that the ACC/AHA makes no recommendation for specific LDL-C or non-hdl targets for the primary and secondary prevention of atherosclerotic CVD. Instead, the focus is on finding the appropriate intensity of statin therapy in order to achieve relative reductions in LDL-C. 1,10 Four groups of primary and secondary prevention patients have been identified. The four major statin groups include: individuals with clinical atherosclerotic CVD; individuals with LDL-C levels at or above 190 mg/dl (such as those with familial hypercholesterolemia); individuals with diabetes ages 40 to 75 years with LDL-C levels between 70 and 189 mg/dl and without evidence of atherosclerotic CVD; and individuals without evidence of CVD or diabetes but who have LDL-C levels between 70 and 189 mg/dl and a 10-year risk of atherosclerotic CVD at or above 7.5%. 1 For patients with diabetes ages 40 to 75 years, a moderateintensity statin (defined as a drug that lowers LDL-C 30% to 49%) should be used. A high-intensity statin is a reasonable choice if the patient also has a 10-year risk of atherosclerotic CVD at or above 7.5%. 1,10 Interventions Lifestyle modification. The ACC/AHA guideline advocates for lifestyle modification as the first step toward improving the lipid profile in patients with T2DM. 1 Lifestyle modifications, including reductions in dietary cholesterol, reductions in saturated and trans fatty acids, and increased physical activity remain central to any therapeutic program. 3 Weight loss (if indicated) and increased physical activity are initially recommended to improve the lipid profile. Additionally, enhanced glycemic control can improve plasma lipid levels, especially in patients with T2DM who have very high TG levels. 2,11 Effective lipid-lowering strategies in patients at high risk for CVD, such as those with T2DM, require the management of not only the LDL-C but also of the HDL-C and TG levels. The American Diabetes Association (ADA) recommends medical nutrition therapy (MNT), which includes a reduction in saturated fat, trans fat, and cholesterol intake. 6 Additionally, the 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk recommends therapeutic lifestyle changes, which include a diet low in saturated fat and cholesterol, use of plant stanols/sterols, and increased consumption of soluble fiber. 11 In addition, the guideline emphasizes weight reduction and exercise/ increased physical activity. TG levels can be decreased and HDL-C levels can be increased with weight loss and increased physical activity. Lifestyle changes may also produce a modest lowering of LDL-C. Also of note, tighter glycemic control can improve plasma lipid levels, especially in patients with T2DM who have very high TG. 2,5,7 Pharmacologic management with statins The ADA recommends pharmacologic (primarily statin) therapy to reduce CVD risk and mortality. 6 Multiple studies have shown significant primary and secondary prevention of CVD events in patients with diabetes who use statins. Meta-analyses from 14 randomized controlled trials of statin therapy demonstrate a 9% proportional reduction in all-cause mortality and 13% reduction in vascular mortality for each mmol/l reduction in LDL-C. There is evidence for significant LDL-C lowering from even extremely low, less than daily statin use. 6 Statin use in patients with diabetes is associated with significant reductions in cardiovascular morbidity and mortality for both primary and secondary prevention. 1,6 Statins inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, inhibiting the rate-limiting step in cholesterol 20 The Nurse Practitioner Vol. 40, No. 8
4 biosynthesis, and competitively inhibiting HMG-CoA reductase. 2,12 Statins primarily lower LDL-C but also have secondary effects of lowering TG and increasing HDL-C levels. Furthermore, statins may increase the particle size of LDL-C to allow less circulation of smaller, dense LDL-C. 5,12 Overall, statins are well tolerated. The more common adverse reactions are headache, nonspecific muscle and joint pain, nausea, diarrhea, constipation, and abdominal pain. Significant elevation of liver enzymes can occur, and discontinuation of statins is recommended when those values reach greater than three times the upper limit of normal. Because of the risk of myopathy and rhabdomyolysis with statin use, patients are encouraged to immediately report any unexplained muscle weakness, tenderness, pain, or fever to their healthcare provider. 12 The benefits of statins outweigh the risks in patients with known CVD. However, new labeling recommended by the FDA, warns of a higher risk of diabetes or cognitive impairment. 13 A slight increase in blood glucose levels and the development of T2DM has been reported in patients who are taking statins. 13 If diabetes occurs or worsens, the statin should not be automatically stopped. It should be explained that statins cardiovascular benefits are even greater in patients with diabetes than those without. 5 Regarding cognitive impairment, the FDA is investigating cognitive impairment associated with statin use. 13 Again, each patient must be considered individually, with risks and benefits fully addressed. Examples of statins include: atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin, and pitavastatin. A baseline lipid profile, serum creatine kinase (CK), liver function tests, and serum creatinine should be obtained before starting statin therapy. Serum CK levels should be checked upon report of any muscle pain or discomfort. Fasting lipid profiles should be measured at least annually in most adult patients with diabetes. 6 The measurement of LDL-C is an important marker of adherence to medication/statin use and one of the best methods of identifying the dose of statin each patient can tolerate. 10 Combination therapy The ADA and ACC/AHA recommendations state that when maximally tolerated, statin doses fail to significantly lower LDL-C (less than 30% reduction from patient s baseline), there is no strong evidence that combination therapy should be used to achieve additional LDL-C lowering. 1,6 The ADA and ACC/AHA further concur that niacin, fenofibrate, ezetimibe, and bile acid sequestrants all offer additional LDL-C lowering to statins alone; however, there is insufficient evidence that such combination therapy for LDL-C lowering provides a significant increment in CVD risk reduction over exclusive statin therapy. 1,6 Special populations and considerations Statins are contraindicated during pregnancy. 1,6,7 Current guidelines recommend discontinuation of the medication immediately upon recognition of pregnancy or before conception if pregnancy is planned. Until more data are available, statins should be avoided during pregnancy, and pregnant women exposed to cholesterol-lowering drugs should be monitored closely. The 2013 ACC/AHA guideline applies to the geriatric population as well. Emphasis is placed on treating dyslipidemia with statins but not to target levels. MNT, supplemented Mediterranean diet, enhanced physical activity, and weight loss have also been shown to play a role in improving cardiovascular risk profiles in older adults with T2DM. 1,14 The American Geriatrics Society guidelines update reinforces glycemic control recommendations customized to burden of comorbidity, functional status, and life expectancy. 14 The update also emphasizes patient-centered recommendations for lifestyle modification because of increased evidence of its importance for healthy older adults with T2DM. 1,6,14 Statin use is supported for lipid-lowering in older adults with T2DM who are younger than 75, but more data are needed for patients age 80 and older. 14 Patient education Providers must continue to educate patients with diabetes about how to manage the risk of macrovascular complications associated with their disease in addition to managing blood glucose and HbA1c. Patients must become actively involved in their care. Each patient s desire to make lifestyle changes should be assessed. Patient education should focus on the importance of adhering to cholesterol-lowering lifestyle changes and medication therapy to help prevent the complications of diabetes that are seen in patients who do not have their lipid levels adequately managed. 12 Motivational interviewing is an excellent technique to consider and utilizes these underlying principles: active listening, expressing empathy, developing discrepancy, avoiding argumentation, rolling with resistance, and supporting self-efficacy (motivationalinterviewing.org). Providers should help the patient identify his or her stage of change and should work as a team to accomplish step-by-step goals toward healthier living. Discussion The prevalence of diabetes has increased dramatically in recent decades. Now is the time to implement prevention and appropriate therapy to reduce cardiovascular events in patients with T2DM. Aggressive treatment of diabetic dyslipidemia, a major modifiable risk factor, will reduce cardiovascular events in this patient population. 1,6,12 The Nurse Practitioner August
5 The LDL-C appears to have the greatest role in premature and early atherosclerosis and the development of CVD. It must be treated as aggressively as hyperglycemia to reduce CVD risk in patients with T2DM. Statin therapy should be added to lifestyle therapy, regardless of baseline lipid levels, for patients with T2DM who have overt CVD or without CVD if they are over 40 years old and have one or more other CVD risk factors, such as a family history of CVD, hypertension, smoking, dyslipidemia, or albuminuria. 6 Becoming familiar with lipid treatment goals/degree of stain intensity and the importance of individualized treatment will result in implementation of the most beneficial, therapeutic approach to dyslipidemia in patients with T2DM. REFERENCES 1. Stone NJ, Robinson J, Lichtenstein AH, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 suppl 2):S Campbell J, Hilleman D. Reducing cardiovascular risk in patients with type 2 diabetes: management of dyslipidemia. Formulary. 2010;45: Ginsberg HN, MacCallum PR. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr. 2009;4(2): Khardori R. Type 2 diabetes mellitus. Medscape Diabetes & Endocrinology Wanner C, Krane V. Recent advances in the treatment of atherogenic dyslipidemia in type 2 diabetes mellitus. Kidney Blood Press Res. 2011;34(4): American Diabetes Association. Position statement. Diabetes Care. 2014;37(suppl 1) Peters A. How do new statin guidelines affect diabetes care? Medscape Diabetes & Endocrinology Parhofer K. Pathophysiology of diabetic dyslipidemia: implications for atherogenesis and treatment. Clin Lipidol. 2011;6(4): McCance KL, Huether SE, Brashers VL, Rote NS, eds. Pathophysiology: The Biologic Basis for Disease in Adults and Children. 6th ed. Maryland Heights, MO: Mosby Elsevier; O Riordan M. New cholesterol guidelines abandon LDL targets. Medscape Cardiology Eckel RH, Jakicic JM, Ard JD, et al. AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 suppl 2):S76-S Daniel MJ. Lipid management in patients with type 2 diabetes. Am Health Drug Benefits. 2011;4(5): U.S. Food and Drug Administration. FDA Expands Advice on Statin Risks Cegelka A. Guidelines abstracted from the American Geriatrics Society Guidelines for improving the care of older adults with diabetes mellitus: 2013 update. J Am Geriatr Soc. 2013;61(11): Michelle L. Frank is a family nurse practitioner student at University of Mary, Bismarck, N.D. Annie M. Gerhardt is adjunct faculty at the University of Mary, Bismarck, N.D. and a family nurse practitioner at Altru Clinic Lake Region, Devils Lake, N.D. The authors and planners have disclosed no potential conflicts of interest, financial or otherwise. DOI /01.NPR c For more than 169 additional continuing education articles related to advanced practice nursing topics, go to NursingCenter.com/CE. Earn CE credit online: Go to and receive a certificate within minutes. INSTRUCTIONS TEST INSTRUCTIONS To take the test online, go to our secure website at On the print form, record your answers in the test answer section of the CE enrollment form on page 23. Each question has only one correct answer. You may make copies of these forms. Complete the registration information and course evaluation. Mail the completed form and registration fee of $21.95 to: Lippincott Williams & Wilkins, CE Group, 74 Brick Blvd., Bldg. 4, Suite 206, Brick, NJ We will mail your certificate in 4 to 6 weeks. For faster service, include a fax number and we will fax your certificate within 2 business days of receiving your enrollment form. You will receive your CE certificate of earned contact hours and an answer key to review your results. There is no minimum passing grade. Registration deadline is August 31, DISCOUNTS and CUSTOMER SERVICE Send two or more tests in any nursing journal published by Lippincott Williams & Wilkins together and deduct $0.95 from the price of each test. We also offer CE accounts for hospitals and other healthcare facilities on nursingcenter.com. Call for details. PROVIDER ACCREDITATION Lippincott Williams & Wilkins, publisher of The Nurse Practitioner journal, will award 2.0 contact hours for this continuing nursing education activity. Lippincott Williams & Wilkins is accredited as a provider of continuing nursing edu cation by the American Nurses Credentialing Center s Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP for 2.0 contact hours. Lippincott Williams & Wilkins is also an approved provider of continuing nursing education by the District of Columbia and Florida # Your certificate is valid in all states. This activity has been assigned 1.0 pharmacology credit. 22 The Nurse Practitioner Vol. 40, No. 8
2.3 CONTACT HOURS. Managing. By Kristine Anne Scordo, PhD, RN, ACNP-BC, FAANP
2.3 CONTACT HOURS 2.3 CONTACT HOURS Managing hyperlipidemia The updated cholesterol treatment guidelines Abstract: The ACC/AHA 2013 cholesterol treatment guidelines focus on lowering the risk of heart
More informationB. Patient has not reached the percentage reduction goal with statin therapy
Managing Cardiovascular Risk: The Importance of Lowering LDL Cholesterol and Reaching Treatment Goals for LDL Cholesterol The Role of the Pharmacist Learning Objectives 1. Review the role of lipid levels
More informationDiabetic Dyslipidemia
Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More informationPIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia
PIEDMONT ACCESS TO HEALTH SERVICES, INC. Policy Number: 01-09-021 SUBJECT: Guidelines for Screening and Management of Dyslipidemia EFFECTIVE DATE: 04/2008 REVIEWED/REVISED: 04/12/10, 03/17/2011, 4/10/2012,
More informationDYSLIPIDEMIA PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
DYSLIPIDEMIA PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Know normal cholesterol levels Understand what the role
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationDiabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018
Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018 Points to Ponder ASCVD is the leading cause of morbidity
More informationManagement of Post-transplant hyperlipidemia
Management of Post-transplant hyperlipidemia B. Gisella Carranza Leon, MD Assistant Professor of Medicine Lipid Clinic - Vanderbilt Heart and Vascular Institute Division of Diabetes, Endocrinology and
More informationMOLINA HEALTHCARE OF CALIFORNIA
MOLINA HEALTHCARE OF CALIFORNIA HIGH BLOOD CHOLESTEROL IN ADULTS GUIDELINE Molina Healthcare of California has adopted the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationAmerican Diabetes Association 2018 Guidelines Important Notable Points
American Diabetes Association 2018 Guidelines Important Notable Points The Standards of Medical Care in Diabetes-2018 by ADA include the most current evidencebased recommendations for diagnosing and treating
More informationWhat do the guidelines say about combination therapy?
What do the guidelines say about combination therapy? Christie M. Ballantyne, MD Center for Cardiovascular Disease Prevention Methodist DeBakey Heart & Vascular Center Baylor College of Medicine Houston,
More informationPharmacy Drug Class Review
Pharmacy Drug Class Review January 22, 2014 Authored By: Christina Manciocchi, Pharm.D. BCACP Disclaimer: Specific agents may have variations Edited By: Richard J. Kraft, Pharm.D.BCPS NEW CHOLESTEROL GUIDELINES
More information2013 ACC/AHA Cholesterol Guidelines JULIE HAMMOND, D.O. PGY-2 MATTHEW PAOLI, D.O. PGY-2
2013 ACC/AHA Cholesterol Guidelines JULIE HAMMOND, D.O. PGY-2 MATTHEW PAOLI, D.O. PGY-2 GOALS ACC/AHA as publisher of guidelines Determining which patients are appropriate for statin therapy The treatment
More informationOriginal paper. Abstract. Abdullah S. Asia 1*, Al-Mahdi A. Modar 2, Hadi M. Ali 3
Original paper Frequency Of Potential Adverse Effects Of A Semisynthetic Statin (Simvastatin) Compared To A Synthetic Statin (Atorvastatin) Used To Reduce Cardiovascular Risk For Patients In Basra 1*,
More informationPrimary Prevention Patients aged 85yrs and over
Rotherham Guideline for the management of Non-Familial Hypercholesterolaemia Type 1 Diabetes Offer lifestyle advice Over 40yrs of age? Diabetic for more than 10 years? Established nephropathy? Other CVD
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationAntihyperlipidemic Drugs
Antihyperlipidemic Drugs Hyperlipidemias. Hyperlipoproteinemias. Hyperlipemia. Hypercholestrolemia. Direct relationship with acute pancreatitis and atherosclerosis Structure Lipoprotein Particles Types
More informationIt is the policy of health plans affiliated with PA Health & Wellness that Vytorin is medically necessary when the following criteria are met:
Clinical Policy: Ezetimibe and Simvastatin (Vytorin) Reference Number: PA.CP.PMN.77 Effective Date: 02.01.17 Last Review Date: 07.18 Revision Log Description Ezetimibe/simvastatin (Vytorin ) contains ezetimibe,
More informationHYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016
HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More information... CPE/CNE QUIZ... CPE/CNE QUESTIONS
CPE/CNE QUESTIONS Continuing Pharmacy Education Accreditation The Virginia Council on Pharmaceutical Education is approved by the American Council on Pharmaceutical Education as a provider of continuing
More informationANTIHYPERLIPIDEMIA. Darmawan,dr.,M.Kes,Sp.PD
ANTIHYPERLIPIDEMIA Darmawan,dr.,M.Kes,Sp.PD Plasma lipids consist mostly of lipoproteins Spherical complexes of lipids and specific proteins (apolipoproteins). The clinically important lipoproteins, listed
More informationNew Guidelines in Dyslipidemia Management
The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationHyperlipidemia. Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi
Hyperlipidemia Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi Outline The story of lipids Definition of hyperlipidemia Classification of hyperlipidemia Causes of hyperlipidemia
More informationClinical Policy: Ezetimibe (Zetia) Reference Number: CP.PMN.78 Effective Date: Last Review Date: 02.19
Clinical Policy: (Zetia) Reference Number: CP.PMN.78 Effective Date: 02.01.17 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationHigh ( 50%) Restrictions mg 20-40mg PA; TS ⱡ 15 ⱡ
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Cholesterol P&T DATE: 5/9/2017 THERAPEUTIC CLASS: Cardiovascular REVIEW HISTORY: 5/16, 5/15, 2/14, 5/12, LOB AFFECTED: Medi-Cal
More informationLipid Guidelines Who, What, and How Low. Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute
Lipid Guidelines Who, What, and How Low Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute Disclosures! None Objectives! List factors used in screening for dyslipidemia
More informationDisclosures. Pediatric Dyslipidemia Casey Elkins, DNP, NP C, CLS, FNLA. Learning Objectives. Atherogenesis. Acceptable Values
39 th National Conference on Pediatric Health Care Pediatric Dyslipidemia Casey Elkins, DNP, NP C, CLS, FNLA March 19-22, 2018 CHICAGO Disclosures Speakers Bureau Sanofi and Regeneron Learning Objectives
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationAntihyperlipidemic drugs
Antihyperlipidemic drugs The clinically important lipoproteins are LDL low density lipoprotein, VLDL very low density lipoprotein, HDL high density lipoprotein. Hyperlipidemia may caused 1. by individual
More informationNew Guidelines in Dyslipidemia Management
The Third IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2017 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationGUIDELINES FOR DYSLIPIDEMIA MANAGEMENT AND EDUCATION THROUGH NOVA SCOTIA DIABETES CENTRES
GUIDELINES FOR DYSLIPIDEMIA MANAGEMENT AND EDUCATION THROUGH NOVA SCOTIA DIABETES CENTRES Prepared by DCPNS Action Committee Dr. Lynne Harrigan Brenda Cook Peggy Dunbar Bev Harpell with the assistance
More informationDYSLIPIDEMIA RECOMMENDATIONS
DYSLIPIDEMIA RECOMMENDATIONS Α. DIAGNOSIS Recommendation 1 INITIAL LIPID PROFILING (Level of evidence II) It is recommended to GPs and other PHC Physicians to assess the lipid profile {total cholesterol
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationPREDIABETES TESTING SERVICES
PREDIABETES TESTING SERVICES ASSESSING DIABETES RISK IN ASYMPTOMATIC ADULTS Depending upon population characteristics, up to 70% of individuals with prediabetes will ultimately progress to diabetes at
More informationAmerican Diabetes Association: Standards of Medical Care in Diabetes 2015
American Diabetes Association: Standards of Medical Care in Diabetes 2015 Synopsis of ADA standards relevant to the 11 th Scope of Work under Task B.2 ASSESSMENT OF GLYCEMIC CONTROL Recommendations: Perform
More informationConflicts of interest. What's the Skinny on the Lipid Guidelines? Key Differences. Are you applying the new ACC/AHA Lipid guidelines in your practice?
Conflicts of interest What's the Skinny on the Lipid Guidelines? The presenter has no relevant conflicts of interest to disclose. Kathleen Vest, PharmD, CDE, BCACP At the end of this presentation, pharmacist
More informationPharmacology Challenges: Managing Statin Myalgia
Clinical Case: RM is a 50 year-old African American woman with a past medical history of type diabetes, dyslipidemia, hypertension and peripheral arterial disease. She had been prescribed simvastatin 80
More informationDiabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology
Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the
More informationSTATIN UTILIZATION MANAGEMENT CRITERIA
STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,
More informationLearning Objectives. Patient Case
Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Learning Objectives Identify the 4 patient populations
More information( Diabetes mellitus, DM ) ( Hyperlipidemia ) ( Cardiovascular disease, CVD )
005 6 69-74 40 mg/dl > 50 mg/dl) (00 mg/dl < 00 mg/dl(.6 mmol/l) 30-40% < 70 mg/dl 40 mg/dl 00 9 mg/dl fibric acid derivative niacin statin fibrate statin niacin ( ) ( Diabetes mellitus,
More informationThe Efficacy and Safety of Statins in the Primary Prevention of Cardiovascular Disease
University of North Dakota UND Scholarly Commons Physician Assistant Scholarly Project Papers Department of Physician Studies 2018 The Efficacy and Safety of Statins in the Primary Prevention of Cardiovascular
More informationAcute Coronary Syndromes (ACS)
Sally A. Arif, Pharm.D., BCPS (AQ Cardiology) Assistant Professor of Pharmacy Practice Midwestern University, Chicago College of Pharmacy Cardiology Clinical Specialist, Rush University Medical Center
More informationDeath is inevitable but premature death is not. Sir Richard Doll
Welcome to the Diabetes Care for You webinar Please log onto the conference call so you can hear our presenter From any SCFT Cisco phone dial 800800 From a mobile phone or any other phone dial 01273 242
More information4/24/15. AHA/ACC 2013 Guideline Key Points
Review of the ACC/AHA 2013 Guidelines Anita Ralstin, MS, CNS, CNP Next Step Health Consultant, LLC 1! Discuss the rationale for the change in lipid guidelines and how that affects the decision to implement
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Vytorin) Reference Number: CP.PMN.77 Effective Date: 02.01.17 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationIndex. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A ACC/AHA. See American College of Cardiology/ ACE inhibitors. See Angiotensin-converting enzyme (ACE) inhibitors American College of Cardiology/American
More informationAntihyperlipidemic Drugs
Antihyperlipidemic Drugs Lipid disorders: Disorders of lipid metabolism are manifest by elevation of the plasma concentrations of the various lipid and lipoprotein fractions (total and LDL cholesterol,
More informationLatest Guidelines for Lipid Management
Latest Guidelines for Lipid Management Goals Recognize the differences between different guidelines Understand the effective strategies to tailor lipid lowering therapies based on evidence and guideline
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationSIGN 149 Risk estimation and the prevention of cardiovascular disease. Quick Reference Guide July Evidence
SIGN 149 Risk estimation and the prevention of cardiovascular disease Quick Reference Guide July 2017 Evidence ESTIMATING CARDIOVASCULAR RISK R Individuals with the following risk factors should be considered
More informationLipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology
Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring
More informationPCSK9 Agents Drug Class Prior Authorization Protocol
PCSK9 Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical
More informationDiabetes Complications Guideline Based Screening, Management, and Referral
Diabetes Complications Guideline Based Screening, Management, and Referral Eric L. Johnson, M.D. Associate Professor Department of Family and Community Medicine Assistant Medical Director Altru Diabetes
More informationCPE Session 7. Update on Clinical Practice Guidelines and Best Evidence in the Management of Hyperlipidemia and Cardiovascular Risk Reduction
CPE Session 7 Update on Clinical Practice Guidelines and Best Evidence in the Management of Hyperlipidemia and Cardiovascular Risk Reduction Saturday, April 25, 2015 ACPE UAN 0128-0000-15-027-L01-P 1.0
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationHighlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM
Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM OSHP 2014 Annual Meeting Oklahoma City, OK April 4, 2014 1 Objectives
More informationJoshua Shepherd PA-C, MMS, MT (ASCP)
Joshua Shepherd PA-C, MMS, MT (ASCP) None What is Cholesterol? Why cholesterol is it important? Review the National Cholesterol Education Programs guidelines (NCEP-ATPIII) Discuss New guidelines from the
More informationConflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines
Conflict of Interest Disclosure Updates for the Ambulatory Care Pharmacist: Dyslipidemia and CV Risk Assessment No conflicts of interest to disclose 2014 Updates to the Updates in Ambulatory Care Pharmacy
More informationPharmacy Management Drug Policy
SUBJECT: ; Praluent (alirocumab), Repatha (evolocumab) POLICY NUMBER: Pharmacy-61 EFFECTIVE DATE: 8/15 LAST REVIEW DATE: 9/22/2017 If the member s subscriber contract excludes coverage for a specific service
More informationIntroduction Hyperlipidemia hyperlipoproteinemia Primary hyperlipidemia (Familial) Secondary hyperlipidemia (Acquired)
Introduction Hyperlipidemia, or hyperlipoproteinemia, is the condition of abnormally elevated levels of any or all lipids and/or lipoproteins in the blood. Hyperlipidemias are divided in primary and secondary
More information4 th and Goal To Go How Low Should We Go? :
4 th and Goal To Go How Low Should We Go? : Evaluating New Lipid Lowering Therapies Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose
More informationObjectives. Having completed the learning activities, the participant will be able to: Dyslipidemia: The latest treatment recommendations
Objectives Dyslipidemia: The latest treatment recommendations Margaret A. Fitzgerald, DNP, FNP-BC, NP-C, FAANP, CSP, FAAN, DCC President, Fitzgerald Health Education Associates, Inc. North Andover, MA
More informationLipids & Hypertension Update
Lipids & Hypertension Update No financial disclosures Michael W. Cullen, MD, FACC Senior Associate Consultant, Assistant Professor of Medicine Mayo Clinic Department of Cardiovascular Diseases 34 th Annual
More informationLearning Objectives. Cholesterol and Lipids in Kids: It s a Matter of the Heart. Is Atherosclerosis a Pediatric Disease?
Scott J. Soifer, MD Professor and Vice Chair Department of Pediatrics University of California, San Francisco UCSF Benioff Children s Hospital Cholesterol and Lipids in Kids: It s a Matter of the Heart
More informationLipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
More informationGuidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AMERICAN COLLEGE OF ENDOCRINOLOGY Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease Writing Committee Chair: Paul S. Jellinger,
More informationPrevention of Heart Disease: The New Guidelines
Prevention of Heart Disease: The New Guidelines Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California San Francisco May 18 th 2015
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationREACH Risk Evaluation to Achieve Cardiovascular Health
Dyslipidemia and transplantation History: An 8-year-old boy presented with generalized edema and hypertension. A renal biopsy confirmed a diagnosis of focal segmental glomerulosclerosis (FSGS). After his
More informationBlood Pressure Measurement (children> 3 yrs)
Blood Pressure Measurement (children> 3 yrs) If initial BP elevated, repeat BP manually 2x and average, then classify Normal BP Systolic and diastolic
More informationComprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium
Comprehensive Treatment for Dyslipidemias Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium Primary Prevention 41 y/o healthy male No Medications Normal BP, Glucose and BMI Social History:
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationClinical Policy: Mipomersen (Kynamro) Reference Number: ERX.SPA.171 Effective Date:
Clinical Policy: (Kynamro) Reference Number: ERX.SPA.171 Effective Date: 01.11.17 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationCardiovascular Risk and Dyslipidemia Management Clinician Guide SEPTEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Cardiovascular Risk and Dyslipidemia Management Clinician Guide SEPTEMBER 2017 Introduction This Clinician Guide is based on the 2017 KP National
More informationAPPENDIX 2F Management of Cholesterol
Patients with established CVD: Coronary heart disease Cerebrovascular disease Peripheral vascular disease APPEDIX 2F Management of Cholesterol Patients at high risk of cardiovascular events: Chronic kidney
More informationThe new guidelines issued in PRESENTATIONS... Future Outlook: Changing Perspectives on Best Practice
... PRESENTATIONS... Future Outlook: Changing Perspectives on Best Practice Based on a presentation by Daniel J. Rader, MD Presentation Summary The guidelines recently released by the National Cholesterol
More informationAn update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine
An update on lipidology and cardiovascular risk management Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine National and international lipid modification guidelines: A critical appraisal
More informationClinical Recommendations: Patients with Periodontitis
The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: Periodontitis and Atherosclerotic Cardiovascular Disease. Friedewald VE, Kornman KS, Beck JD, et al. J Periodontol 2009;
More informationClinical Policy: Lomitapide (Juxtapid) Reference Number: ERX.SPA.170 Effective Date:
Clinical Policy: (Juxtapid) Reference Number: ERX.SPA.170 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More information2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries
Lipid Disorders in Diabetes (Diabetic Dyslipidemia) Khosrow Adeli PhD, FCACB, DABCC Head and Professor, Clinical Biochemistry, The Hospital for Sick Children, University it of Toronto Diabetes A Global
More informationLipoprotein Particle Profile
Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2063-8 Program Prior Authorization/Medical Necessity Medication Repatha (evolocumab) P&T Approval Date 5/2015, 9/2015, 11/2015,
More informationClinical Policy: Pitavastatin (Livalo), Ezetimibe/Simvastatin (Vytorin 10/10 mg) Reference Number: CP.CPA.62 Effective Date:
Clinical Policy: Pitavastatin (Livalo), Ezetimibe/Simvastatin (Vytorin 10/10 mg) Reference Number: CP.CPA.62 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See
More informationDyslipedemia New Guidelines
Dyslipedemia New Guidelines New ACC/AHA Prevention Guidelines on Blood Cholesterol November 12, 2013 Mohammed M Abd El Ghany Professor of Cardiology Cairo Universlty 1 1 0 Cholesterol Management Pharmacotherapy
More informationRosuvastatin 5 mg, 10 mg and 20 mg Tablet
Rosuvastatin 5 mg, 10 mg and 20 mg Tablet Description is a preparation of Rosuvastatin. Rosuvastatin is a member of the drug class of statins, used in combination with exercise, diet, and weight-loss to
More informationLipid Management 2013 Statin Benefit Groups
Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2062-8 Program Prior Authorization/Medical Necessity Medication Praluent (alirocumab) P&T Approval Date 5/2015, 8/2015, 9/2015,
More informationMacrovascular Management. What s next beyond standard treatment?
Macrovascular Management What s next beyond standard treatment? Are Lifestyle Modifications Still Relevant in Diabetic Patients? Diet Omega-6 and omega-3 fatty acids have been shown to improve CVD risk
More informationDisclosures. Prevention of Heart Disease: The New Guidelines. Summary of Talk. Four guidelines. No relevant disclosures.
Disclosures Prevention of Heart Disease: The New Guidelines No relevant disclosures Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California
More informationMacronutrients and Dietary Patterns for Glucose Control
제 20 회대한당뇨병학회춘계학술대회 Macronutrients and Dietary Patterns for Glucose Control 2017.5.13 서울대학교병원임정현 Conflict of interest disclosure None Committee of Scientific Affairs Contents Review of Nutrition Recommendation
More informationhyperlipidemia in CKD DR MOJGAN MORTAZAVI ASSOCIATE PROFESSOR OF NEPHROLOGY ISFAHAN KIDNEY DISEASES RESEARCH CENTER
Management of hyperlipidemia in CKD DR MOJGAN MORTAZAVI ASSOCIATE PROFESSOR OF NEPHROLOGY ISFAHAN KIDNEY DISEASES RESEARCH CENTER Background on Dyslipidemia in CKD In advanced chronic kidney disease (CKD),
More informationDyslipidemia and HIV NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Dyslipidemia and HIV Heidi Crane, MD, MPH Madison Metabolic Clinic Associate Professor UW Department of Medicine Presentation prepared by: Heidi Crane, MD,
More information